Comments
Drug firm Orchid Chemicals & Pharmaceuticals has received nod from the US health regulator USFDA for generic anti-bacterial Gemifloxacin Mesylate tablets.
The company has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Gemifloxacin Mesylate tablets in the strength of 320 mg, Orchid Chemicals & Pharmaceuticals said in a filing to BSE.
The approval is with 180 days of generic drug exclusivity, it added.
Chennai-based Orchid Chemicals is present in segments such as anti-infective, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products.
Shares of Orchid Chemicals & Pharmaceutical today closed at Rs 49.35 on the BSE, up 9.30 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.